VNDA Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1347178 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.1%
TTM net income YoY-226.4%
TTM EPS YoY-220.8%
Revenue 3-yr CAGR2.7%
Net income 3-yr CAGR—
Margins
Gross margin93.6%
Operating margin-77.6%
Net margin-119.9%
FCF margin-61.0%
EBITDA margin-77.1%
Returns
ROE-82.5%
ROA-55.9%
ROIC (approx.)-52.6%
Asset turnover0.47x
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.00x
Current ratio1.54x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.51x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue0.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $69.81M | $50.53M | $51.72M | $57.22M | $56.26M | $52.59M | $50.04M | $53.19M |
| Cost of revenue | $4.15M | $3.56M | $3.16M | $3.83M | $2.95M | $2.74M | $3.52M | $2.59M |
| Gross profit | $65.66M | $46.97M | $48.56M | $53.38M | $53.30M | $49.85M | $46.52M | $50.59M |
| R&D expense | $27.62M | $36.95M | $28.43M | $29.01M | $22.56M | $21.99M | $35.71M | $19.84M |
| SG&A expense | $59.58M | $71.84M | $68.36M | $62.98M | $60.27M | $64.62M | $50.08M | $39.28M |
| Operating income | -$23.52M | -$63.81M | -$50.22M | -$40.35M | -$31.28M | -$38.50M | -$41.03M | -$10.28M |
| Pretax income | -$22.39M | -$62.38M | -$48.42M | -$38.00M | -$28.39M | -$34.89M | -$37.37M | -$6.50M |
| Income tax | $174,000 | $129,000 | $143,000 | $103.19M | -$5.80M | -$7.68M | -$7.87M | -$1.58M |
| Net income | -$22.56M | -$62.51M | -$48.57M | -$141.19M | -$22.59M | -$27.21M | -$29.49M | -$4.91M |
| EBITDA | -$23.28M | -$63.54M | -$49.95M | -$40.05M | -$30.98M | -$38.24M | -$40.80M | -$10.06M |
| EPS (basic) | -0.37 | -1.04 | -0.82 | — | -0.38 | -0.46 | -0.50 | — |
| EPS (diluted) | -0.37 | -1.04 | -0.82 | — | -0.38 | -0.46 | -0.50 | — |
| Weighted avg. shares (diluted) | 60.47M | 60.23M | 59.46M | — | 59.09M | 58.99M | 58.53M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $61.93M | $55.88M | $54.03M | $84.85M | $70.02M | $80.98M | $111.80M | $102.78M |
| Receivables | $60.32M | $59.69M | $56.88M | $54.58M | $50.54M | $44.99M | $44.60M | $47.10M |
| Inventory | $1.53M | $1.68M | $1.70M | $1.85M | $2.04M | $2.17M | $1.92M | $1.73M |
| Current assets | $238.47M | $264.48M | $293.17M | $347.26M | $367.50M | $394.92M | $407.91M | $438.89M |
| PP&E, net | $3.03M | $2.58M | $2.25M | $2.25M | $2.46M | $2.42M | $2.44M | $2.13M |
| Intangibles | $111.13M | $113.11M | $115.10M | $117.09M | $108.84M | $110.59M | $112.34M | $114.10M |
| Total assets | $382.33M | $412.47M | $433.52M | $488.95M | $601.14M | $624.75M | $631.94M | $656.20M |
| Current liabilities | $154.98M | $164.03M | $135.58M | $145.16M | $117.87M | $121.49M | $103.92M | $99.98M |
| Total liabilities | $182.47M | $192.28M | $152.76M | $161.76M | $135.14M | $138.42M | $120.52M | $117.66M |
| Shareholders' equity | $199.86M | $220.19M | $280.76M | $327.19M | $466.00M | $486.33M | $511.42M | $538.55M |
| Shares outstanding | 60.47M | 60.45M | 60.14M | 59.10M | 59.10M | 59.08M | 58.93M | 58.31M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.43M | -$31.07M | -$50.22M | -$29.42M | -$31.63M | -$15.25M | -$33.15M | -$1.82M |
| Capital expenditure | $311,000 | $190,000 | $221,000 | $102,000 | $161,000 | $299,000 | $436,000 | $214,000 |
| Free cash flow | -$28.75M | -$31.26M | -$50.44M | -$29.52M | -$31.79M | -$15.55M | -$33.58M | -$2.03M |
| Investing cash flow | $35.21M | $33.81M | $20.23M | $44.87M | $21.36M | -$15.27M | $43.90M | $3.99M |
| Financing cash flow | -$877,000 | -$856,000 | -$776,000 | -$640,000 | -$517,000 | -$425,000 | -$1.32M | -$155,000 |
| Depreciation & amortization | $243,000 | $267,000 | $273,000 | $304,000 | $301,000 | $267,000 | $231,000 | $221,000 |
| Stock-based compensation | $2.34M | $2.11M | $2.56M | $2.29M | $2.11M | $2.11M | $2.97M | $2.86M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.